Phaseline

Companies › COMPASS Pathways

COMPASS Pathways: clinical trials, targets and expected readouts

1 active drug program in 98 registered trials: 55 Phase 2, 34 Phase 1, 9 Phase 3; Neurology, Immunology, Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Psilocybin (COMP360)
Serotonin 2a (5-HT2a) receptor agonist
HTR2APhase 3Treatment Resistant Depression; Major Depressive Disorder; PTSD - Post Traumatic Stress Disorder; Depressive Disorder, Major …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04410913Psilocybin (COMP360)Phase 2Alcohol Use DisorderPsychiatryFeb 2023
NCT05421065Psilocybin (COMP360)Phase 2Alcohol Use DisorderPsychiatryAug 2025
NCT05733546Psilocybin (COMP360)Phase 2Major Depressive DisorderPsychiatrySep 2025
NCT06899334Psilocybin (COMP360)Phase 1HealthyOtherAug 2026
NCT06796361Psilocybin (COMP360)Phase 1HealthyOtherAug 2026
NCT05585229Psilocybin (COMP360)Phase 2Opioid DependencePsychiatryAug 2026
NCT07079930Psilocybin (COMP360)Phase 1Healthy VolunteersOtherNov 2026
NCT06898606Psilocybin (COMP360)Phase 1Depressive DisorderPsychiatryNov 2026
NCT07336238Psilocybin (COMP360)Phase 2AnxietyOncologyDec 2026
NCT05711940Psilocybin (COMP360)Phase 3Treatment Resistant DepressionPsychiatryDec 2026
NCT06416085Psilocybin (COMP360)Phase 2Advanced CancerOncologyDec 2026
NCT06319378Psilocybin (COMP360)Phase 2MDDOncologyDec 2026
NCT06888128Psilocybin (COMP360)Phase 2PTSDPsychiatryDec 2026
NCT06888128Psilocybin (COMP360)Phase 2PTSDPsychiatryDec 2026
NCT06731335Psilocybin (COMP360)Phase 2Chronic Neuropathic PainNeurologyDec 2026
NCT06225232Psilocybin (COMP360)Phase 2Cannabis Use Disorder, ModerateOncologyDec 2026
NCT06815653Psilocybin (COMP360)Phase 1HealthyOtherDec 2026
NCT06430541Psilocybin (COMP360)Phase 1Breast CancerOncologyDec 2026
NCT03554174Psilocybin (COMP360)Phase 1Major Depressive DisorderPsychiatryDec 2026
NCT03554174Psilocybin (COMP360)Phase 1Major Depressive DisorderPsychiatryDec 2026
NCT04161066Psilocybin (COMP360)Phase 1Opioid Use DisorderPsychiatryDec 2026
NCT06341426Psilocybin (COMP360)Phase 2Major Depressive DisorderPsychiatryDec 2026
NCT06367738Psilocybin (COMP360)Phase 1AgingOtherDec 2026
NCT05403086Psilocybin (COMP360)Phase 2DemoralizationPsychiatryDec 2026
NCT06378229Psilocybin (COMP360)Phase 2Treatment Resistant DepressionPsychiatryDec 2026
NCT06200155Psilocybin (COMP360)Phase 2Depression, AnxietyPsychiatryDec 2026
NCT06001749Psilocybin (COMP360)Phase 2Opioid-Related DisordersOncologyDec 2026
NCT04982796Psilocybin (COMP360)Phase 1Amphetamine-Related DisordersPsychiatryDec 2026
NCT05398484Psilocybin (COMP360)Phase 2Advanced CancerOncologyJan 2027
NCT06782724Psilocybin (COMP360)Phase 2COPD (Chronic Obstructive Pulmonary Disease)NeurologyJan 2027
NCT06506019Psilocybin (COMP360)Phase 1Bipolar DepressionPsychiatryJan 2027
NCT04754061Psilocybin (COMP360)Phase 1Depression, AnxietyPsychiatryJan 2027
NCT06731621Psilocybin (COMP360)Phase 1Treatment Resistant DepressionPsychiatryJan 2027
NCT06160284Psilocybin (COMP360)Phase 1Opioid Use DisorderPsychiatryJan 2027
NCT06308653Psilocybin (COMP360)Phase 3Depressive Disorder, MajorPsychiatryJan 2027
NCT05698511Psilocybin (COMP360)Phase 1Psychedelic ExperiencesOtherJan 2027
NCT05370911Psilocybin (COMP360)Phase 1Obsessive-Compulsive DisorderPsychiatryFeb 2027
NCT06518720Psilocybin (COMP360)Phase 2Treatment Resistant DepressionPsychiatryMar 2027
NCT07332143Psilocybin (COMP360)Phase 2PTSDPsychiatryMar 2027
NCT06303739Psilocybin (COMP360)Phase 3Refractory DepressionPsychiatryMar 2027
NCT06801041Psilocybin (COMP360)Phase 2DepressionOncologyMar 2027
NCT06512220Psilocybin (COMP360)Phase 2Treatment Resistant DepressionPsychiatryApr 2027
NCT05947383Psilocybin (COMP360)Phase 2CancerOncologyApr 2027
NCT06810310Psilocybin (COMP360)Phase 2Opioid Use DisorderPsychiatryMay 2027
NCT07506395Psilocybin (COMP360)Phase 1PTSDPsychiatryMay 2027
NCT04882839Psilocybin (COMP360)Phase 2Obsessive-compulsive DisorderPsychiatryJun 2027
NCT07183748Psilocybin (COMP360)Phase 2Treatment Resistant DepressionPsychiatryJun 2027
NCT06853912Psilocybin (COMP360)Phase 2Alcohol Use Disorder (AUD)PsychiatryJun 2027
NCT06786325Psilocybin (COMP360)Phase 2Opioid Use DisorderPsychiatryJun 2027
NCT06455293Psilocybin (COMP360)Phase 2Parkinson DiseaseNeurologyJun 2027
NCT07063862Psilocybin (COMP360)Phase 3Psychological DistressOtherAug 2027
NCT06233344Psilocybin (COMP360)Phase 2Mental HealthPsychiatryAug 2027
NCT07169747Psilocybin (COMP360)Phase 2Anorexia NervosaPsychiatryOct 2027
NCT07703722Psilocybin (COMP360)Phase 3Major Depressive DisorderPsychiatryOct 2027
NCT07216404Psilocybin (COMP360)Phase 2Lung Non-Small Cell CarcinomaOncologyOct 2027
NCT06902974Psilocybin (COMP360)Phase 2Post Traumatic Stress DisorderPsychiatryNov 2027
NCT07818564Psilocybin (COMP360)Phase 1Phase IOtherNov 2027
NCT05866471Psilocybin (COMP360)Phase 1HealthyOtherNov 2027
NCT06626139Psilocybin (COMP360)Phase 2Healthy Participants With Lower-than-average Mental Well-beingOtherNov 2027
NCT07281352Psilocybin (COMP360)Phase 1Major Depressive DiorderPsychiatryNov 2027

The 60 nearest readouts of 98 trials; the rest in the app.

From the company's SEC filings

Cash of $444m on 2026-09-30; operating cash outflow about $187m a year; runway about 29 months at that burn, to Feb 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

HTR2A (1)

Companies with the same targets

Cybin IRL ACADIA Pharmaceuticals Vanda Pharmaceuticals Intra-Cellular Therapies Definium Therapeutics US Sichuan Kelun Pharmaceutical Boryung Pharmaceutical Otsuka NeuroRx Tonix Pharmaceuticals

Companies built like this

Cybin IRL Lipocine Cartesian Therapeutics Xenon Pharmaceuticals Laboratorios Silanes S.A. de C.V.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.